Sangamo Therapeutics announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Click here to view

Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares